

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



PRODUCT INFORMATION



Rivaroxaban-d₄

Item No. 22563

CAS Registry No.: 1132681-38-9

5-chloro-N-[[(5S)-2-oxo-3-[4-(3-oxo-4-Formal Name:

morpholinyl)phenyl-2,3,5,6-d₄]-5-oxazolidinyl]

methyl]-2-thiophenecarboxamide

MF: $\mathsf{C}_{19}\mathsf{H}_{14}\mathsf{CID}_4\mathsf{N}_3\mathsf{O}_5\mathsf{S}$

439.9 FW:


Chemical Purity: ≥98% (Rivaroxaban)

Deuterium

Incorporation: \geq 99% deuterated forms (d₁-d₄); \leq 1% d₀

Supplied as: A solid -20°C Storage: Stability: ≥2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

Rivaroxaban-d₁ is intended for use as an internal standard for the quantification of rivaroxaban (Item No. 16043) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Rivaroxaban- d_4 is supplied as a solid. A stock solution may be made by dissolving the rivaroxaban- d_4 in the solvent of choice. Rivaroxaban-d₁ is soluble in the organic solvent DMSO, which should be purged with an inert gas.

Description

Rivaroxaban is an orally active, direct inhibitor of Factor Xa (K_i = 0.4 nM), which is a crucial component of the intrinsic and extrinsic pathways of the blood coagulation cascade. 1 It demonstrates >10,000-fold greater selectivity for Factor Xa compared to other related serine proteases. In various animal arterial and venous thrombosis models, rivaroxaban is reported to inhibit thrombin formation without prolonging bleeding time. Formulations containing rivaroxaban have been used as an anticoagulant in the prevention of stroke and the treatment of venous thromboembolisms.^{2,3}

References

- 1. Turpie, A.G.G. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler. Thromb. Vasc. Biol. 27(6), 1238-1247 (2007).
- Babilonia, K. and Trujillo, T. The role of prothrombin complex concentrates in reversal of target specific anticoagulants. Thromb. J. 12:8 (2014).
- Turpie, A.G.G. Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation. Ther. Clin. Risk Manag. 10, 197-205 (2014).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 11/29/2017

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM